Abstract
The clinical, immunologic, and virologic effects and the pharmacokinetics of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin (HIVIG) were assessed in 30 HIV-infected children aged 2-11 years. All had moderately advanced disease with an immune complex- dissociated (ICD) p24 antigen >70 pg/mL and were on stable antiviral therapy. Three groups of 10 children received 6 monthly infusions of 200, 400, or 800 mg/kg of HIVIG, and serial immunologic and virologic assays were performed. HIVIG doses as high as 800 mg/kg were safe and well tolerated. The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6- 6.0 mL/kg/day. Plasma ICD p24 decreased during the infusions, but CD4 cell levels, plasma RNA copy number, cellular virus, immunoglobulin levels, and neutralizing antibody titers were minimally affected by the infusions. Clinical status did not change during the 6-month infusion and 3-month follow-up periods.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 548-554 |
| Number of pages | 7 |
| Journal | Journal of Infectious Diseases |
| Volume | 181 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 15 2000 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases
Cite this
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS Clinical Trials Group Protocol 273). / Stiehm, E. Richard; Fletcher, Courtney V; Mofenson, Lynne M.; Palumbo, Paul E.; Kang, Minhee; Fenton, Terry; Sapan, Christine V.; Meyer, William A.; Shearer, William T.; Hawkins, Elizabeth; Fowler, Mary Glenn; Bouquin, Pamela; Purdue, Lynette; Sloand, Elaine M.; Nemo, George J.; Wara, Diane; Bryson, Yvonne J.; Starr, Stuart E.; Petru, Ann; Burchett, Sandra.
In: Journal of Infectious Diseases, Vol. 181, No. 2, 15.03.2000, p. 548-554.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS Clinical Trials Group Protocol 273)
AU - Stiehm, E. Richard
AU - Fletcher, Courtney V
AU - Mofenson, Lynne M.
AU - Palumbo, Paul E.
AU - Kang, Minhee
AU - Fenton, Terry
AU - Sapan, Christine V.
AU - Meyer, William A.
AU - Shearer, William T.
AU - Hawkins, Elizabeth
AU - Fowler, Mary Glenn
AU - Bouquin, Pamela
AU - Purdue, Lynette
AU - Sloand, Elaine M.
AU - Nemo, George J.
AU - Wara, Diane
AU - Bryson, Yvonne J.
AU - Starr, Stuart E.
AU - Petru, Ann
AU - Burchett, Sandra
PY - 2000/3/15
Y1 - 2000/3/15
N2 - The clinical, immunologic, and virologic effects and the pharmacokinetics of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin (HIVIG) were assessed in 30 HIV-infected children aged 2-11 years. All had moderately advanced disease with an immune complex- dissociated (ICD) p24 antigen >70 pg/mL and were on stable antiviral therapy. Three groups of 10 children received 6 monthly infusions of 200, 400, or 800 mg/kg of HIVIG, and serial immunologic and virologic assays were performed. HIVIG doses as high as 800 mg/kg were safe and well tolerated. The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6- 6.0 mL/kg/day. Plasma ICD p24 decreased during the infusions, but CD4 cell levels, plasma RNA copy number, cellular virus, immunoglobulin levels, and neutralizing antibody titers were minimally affected by the infusions. Clinical status did not change during the 6-month infusion and 3-month follow-up periods.
AB - The clinical, immunologic, and virologic effects and the pharmacokinetics of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin (HIVIG) were assessed in 30 HIV-infected children aged 2-11 years. All had moderately advanced disease with an immune complex- dissociated (ICD) p24 antigen >70 pg/mL and were on stable antiviral therapy. Three groups of 10 children received 6 monthly infusions of 200, 400, or 800 mg/kg of HIVIG, and serial immunologic and virologic assays were performed. HIVIG doses as high as 800 mg/kg were safe and well tolerated. The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6- 6.0 mL/kg/day. Plasma ICD p24 decreased during the infusions, but CD4 cell levels, plasma RNA copy number, cellular virus, immunoglobulin levels, and neutralizing antibody titers were minimally affected by the infusions. Clinical status did not change during the 6-month infusion and 3-month follow-up periods.
UR - http://www.scopus.com/inward/record.url?scp=0034005712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034005712&partnerID=8YFLogxK
U2 - 10.1086/315224
DO - 10.1086/315224
M3 - Article
VL - 181
SP - 548
EP - 554
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 2
ER -